Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) EBIT: 2019-2025

Historic EBIT for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$126.8 million.

  • Beam Therapeutics' EBIT fell 19.07% to -$126.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$466.3 million, marking a year-over-year decrease of 155.26%. This contributed to the annual value of -$415.6 million for FY2024, which is 135.47% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' EBIT is -$126.8 million, which was down 5.54% from -$120.2 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' EBIT peaked at $132.9 million during Q4 2023, and registered a low of -$200.4 million during Q1 2021.
  • Moreover, its 3-year median value for EBIT was -$104.9 million (2024), whereas its average is -$87.1 million.
  • As far as peak fluctuations go, Beam Therapeutics' EBIT plummeted by 606.66% in 2021, and later surged by 249.30% in 2023.
  • Beam Therapeutics' EBIT (Quarterly) stood at -$63.5 million in 2021, then plummeted by 40.17% to -$89.0 million in 2022, then soared by 249.30% to $132.9 million in 2023, then plummeted by 175.30% to -$100.0 million in 2024, then decreased by 19.07% to -$126.8 million in 2025.
  • Its EBIT stands at -$126.8 million for Q3 2025, versus -$120.2 million for Q2 2025 and -$119.3 million for Q1 2025.